Answers are grounded in this paper and cite their sources.
A diiron(III)-gaticarboxylic acid (H-Gat) complex, [Fe2(Gat)4(μ-OCH3)2] (FeGa1), (H-Gat = 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-3-quinolinecarboxylic acid), was designed, and its antiproliferative activity was evaluated and compared to that of the 5,7-dichloro-2-methyl-8-quinolinol (H-Dmq) diiron(III) complex [Fe2(Dmq)4(μ-O)] (FeGa2). Compared to the ligands H-Gat and H-Dmq, complex FeGa1 showed higher cytotoxicity towards human cervical SiHa cancer cells, with an IC50 value of 0.11 ± 0.01 μM (cisplatin (CPL): 10.29 ± 0.46 μM and FeGa2: 2.15 ± 0.72 μM). Mechanistic studies indicated that FeGa1 and FeGa2 can trigger SiHa cell apoptosis and senescence by activating caspase-3/7, inducing DNA damage and inhibiting hTERT, with their activity following the order FeGa1 > FeGa2. According to an iron (Fe) uptake assay, FeGa1 showed significantly higher cellular Fe accumulation in the nuclear fraction than FeGa2; this difference can be unambiguously attributed to the chelating properties conferred by the H-Gat ligand in FeGa1. This may well explain the higher cytotoxicity and more significant anticancer activity of FeGa1 throughout the study. Importantly, compound FeGa1 with the H-Gat ligand was selected for an in vivo test, in which it showed a tumor growth inhibition rate (TGIR) of ca. 52.9%. Overall, the diiron(III)-H-Gat complex FeGa1 demonstrates promising potential as a potent antiproliferative agent.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: